Hester Biosciences Ltd (BSE: 524669) is a Mehsana, Gujarat-based company in the Biological Products industry. With a market capitalisation of ₹1,985 Cr, it ranks #1,248 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 5 in Biological Products. At ₹2,332.00 (as of 16 Nov 2026), the share price is 13.1% below its 52-week high of ₹2,683.60 and 88.2% above its 52-week low of ₹1,239.30. The share price is up 46.0% over one year and down 5.6% over three months.
| Current Price | ₹2,332.00 |
|---|---|
| Market Cap | ₹1,985 Cr |
| BSE Code | 524669 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | 35.7 |
| Return on Equity | 16.55% |
| Return on Assets | 6.51% |
| 52-Week Range | ₹1,239.30 – ₹2,683.60 |
| 1-Year Price Change | +46.0% |
| 3-Month Price Change | -5.6% |
| Beta (1Y) | -0.06 |
| Dividend Yield | 0.47% |
| Headquarters | Mehsana, Gujarat |
| Website | www.hester.in |
| Revenue | ₹98 Cr |
|---|---|
| Net Profit | ₹21 Cr |
| Net Margin | 21.1% |
| EPS (Basic) | ₹23.94 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Hester Biosciences Ltd reported revenue of ₹98 Cr in Q2 FY27, up 38.0% from ₹71 Cr in Q2 FY26 and up 26.8% from ₹77 Cr in Q1 FY27. It posted a net profit of ₹21 Cr for the quarter, against a net profit of ₹14 Cr in Q2 FY26 (up 44.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹71 Cr (Q2 FY26) to ₹100 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹98 Cr | ₹21 Cr | 21.1% |
| Q1 FY27 | ₹77 Cr | ₹97 Cr | 125.2% |
| Q4 FY26 | ₹100 Cr | ₹17 Cr | 16.5% |
| Q3 FY26 | ₹77 Cr | ₹9 Cr | 12.0% |
| Q2 FY26 | ₹71 Cr | ₹14 Cr | 20.2% |
| Q1 FY26 | ₹84 Cr | ₹17 Cr | 20.6% |
| Q4 FY25 | ₹82 Cr | ₹2 Cr | 1.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 44.28% of Hester Biosciences Ltd's shares as of Sept 2026, against 53.73% in Sept 2025 (−9.45 percentage points). Delivery averaged 55.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek’s disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella abortus, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming aids,
1. Poultry Healthcare-This segment engages in manufacturing poultry vaccines; and trading of poultry. 2. Animal Healthcare-This segment engages in manufacturing of large animal vaccines; and trading of large animal health products. 3. Unallocated Assets-0 4. Segment Adjustment-0
1. Poultry Healthcare-61.9% 2. Animal Healthcare-38.1%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Biocon Limited | ₹59,929 Cr | 131.2 | 1.15% | ₹4,389 Cr | -4.3% |
| Hester Biosciences Ltd | ₹1,985 Cr | 35.7 | 16.55% | ₹98 Cr | +46.0% |
| Zenotech Laboratories Ltd | ₹241 Cr | n/m | -1.12% | — | -22.5% |
| Transgene Biotek Ltd. | ₹19 Cr | n/m | -17.96% | ₹0 Cr | -22.1% |
| Hindustan Bio Sciences Ltd | ₹7 Cr | n/m | -9.12% | — | -0.4% |
Listed by market capitalisation. Ratios are shown for context only.
Hester Biosciences Ltd is trading at ₹2,332.00, with a market capitalisation of ₹1,985 Cr.
Hester Biosciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Hester Biosciences Ltd has a P/E of 35.7 and a return on equity of 16.55%.
Hester Biosciences Ltd is listed on the BSE under the scrip code 524669.
Hester Biosciences Ltd's share price is up 46.0% over one year and down 5.6% over three months. Its 52-week range is ₹1,239.30 to ₹2,683.60.
In Q2 FY27, Hester Biosciences Ltd reported revenue of ₹98 Cr and net profit of ₹21 Cr, with basic EPS of ₹23.94 (consolidated, parsed from the company's exchange filing).
Hester Biosciences Ltd reported revenue of ₹98 Cr in Q2 FY27, up 38.0% from ₹71 Cr in Q2 FY26 and up 26.8% from ₹77 Cr in Q1 FY27.
Promoters held 44.28% of Hester Biosciences Ltd's shares as of Sept 2026, against 53.73% in Sept 2025 (−9.45 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.